September 23, 2020 -- A phase III clinical trial evaluating the investigational Janssen COVID-19 vaccine Ad26.COV2.S for the prevention of symptomatic COVID-19 in a single-dose regimen has begun.
The trial is part of Operation Warp Speed (OWS) and is being funded by Johnson & Johnson (a Janssen company); the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH); and the Biomedical Advanced Research and Development Authority (BARDA), a U.S. federal health agency.
The study will enroll up to 60,000 volunteers at nearly 215 clinical research sites in the U.S. and internationally. The trial sites are part of an NIAID-supported COVID-19 Prevention Network.
The Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership will ensure the protocols of all NIH- and OWS-supported phase III trials of investigational vaccines use the same assays and enables transparent evaluation of vaccines across trials.
Johnson & Johnson's vaccine candidate is a recombinant vector vaccine that uses human adenovirus to express the SARS-CoV-2 spike protein in cells. Preclinical data demonstrated that the vaccine induced neutralizing antibody responses in rhesus macaques and provided complete or near-complete protection against the virus in the lungs and nose. Interim results from an ongoing phase I/IIA trial in the U.S. and Belgium indicate that the vaccine has a positive safety profile and immunogenicity after a single vaccination.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
